NCT04991506已完成1 期
An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 in Combination With JS001 in Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- MTD
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 agonist) in combination with JS001 (anti-PD-1 checkpoint inhibitor) in patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Males or females aged ≥18 years.
- •2.Ability to understand and the willingness to sign a written informed consent form.
- •3.Subjects with pathological or cytological diagnosed advanced solid tumor, whose disease has progressed despite standard therapies, or for whom no further standard therapy exists, or who is unsuitable for available standard therapies and at least has progressed after receiving first line therapy.
- •4.PD-L1 by IHC: Parts 1 and Part 2 D2-D3: IHC result mandatory but any score allowed. Part 2 D1: Tumor Proportion Score (TPS) ≥ 1%.
- •5.At least one measurable lesion is required (RECIST v1.1)
- •6.Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
- •7.Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or
- •8.Estimated life expectancy, in the judgment of the investigator, of at least 12 weeks.
- •9.Male and female subjects of childbearing potential and their spouses must be willing to use feasible contraceptive methods considered effective by the investigator, from the time of signing informed consent and for the duration of study participation through 3 months, following the last dose of study drug. Postmenopausal women are considered to have no fertility potential only if menostasis lasts for at least 12 months.
排除标准
- •1.Prior exposure to OX40 agonists.
- •2.Receipt of any anticancer investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- •3.Receipt of non-CNS adjuvant radiation therapy within 1 week prior to the first dose, receipt of radiation therapy within 2 weeks or with radiation pneumonia, have not recovered from radiation-related toxicity or still require hormonal treatment for radiation-related toxicity.
- •4.Known allergies to CHO-produced antibodies, which in the opinion of the Investigator suggests an increased potential for an adverse hypersensitivity to ES
- •5.Subjects with allergic reactions to the active ingredients of JS001 or any of the excipients.
- •6.Treatment with systemic immunosuppressive medications within 4 weeks prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- •7.Receipt of live viral vaccine treatment within 4 weeks prior to the first dose of the study drug.
- •8.Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- •9.Subjects with primary or metastatic brain or meningeal tumors.
- •10.Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- •11.Subject has not recovered from all AEs of previous anticancer therapies to baseline or ≤ Grade 1 per CTCAE v5.0 before the first dose of study drug. Certain exceptions as defined in protocol apply.
- •12.Hematologic malignancies.
- •13.Receipt of treatment with G-CSF, GM-CSF, Thrombopoietic drugs or EPO within 14 days prior to the first dose of the study drug.
- •14.Patients with other malignancies within 2 years before screening shall be excluded in Part B. Some exceptions as defined per protocol apply.
- •15.Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- •16.Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- •17.Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease < 6 months; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension.
- •18.History of pulmonary embolism within 12 weeks prior to the first dose of study drug administration.
- •19.Major surgery within 4 weeks prior to enrollment on this trial.
- •20.History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection for Part
- •Exceptions as defined in protocol for Part 2 will apply.
- •21.Receiving the systemic anti-infectious drug treatments within 4 weeks prior to the first dose of study drug.
- •22.Pregnant or nursing females.
- •23.Any known, documented, or suspected history of substance abuse that would preclude subject from participation, certain exceptions as defined in protocol apply.
- •24.The subject is inappropriate to participate in this study for other reasons in the judgment of the Investigator.
研究组 & 干预措施
Part 1 ES102 Escalation in combination with JS001
Experimental
ES102 will be escalated, in combination with JS001, in patients with advanced solid tumors.
干预措施: ES102 (Drug)
Part 1 ES102 Escalation in combination with JS001
Experimental
ES102 will be escalated, in combination with JS001, in patients with advanced solid tumors.
干预措施: JS001 (Drug)
Part 2 ES102 Expansion in combination with JS001
Experimental
Subjects will be treated with ES102 at the RP2D in combination with JS001.
干预措施: ES102 (Drug)
Part 2 ES102 Expansion in combination with JS001
Experimental
Subjects will be treated with ES102 at the RP2D in combination with JS001.
干预措施: JS001 (Drug)
结局指标
主要结局
MTD
时间窗: 2-4 years
Maximum Tolerated Dose (MTD) of ES102 in combination with JS001
Frequency and severity of adverse events of ES102 in combination with JS001
时间窗: 2-4 years
The safety profile of ES102 in combination with JS001 will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
RP2D
时间窗: 2-4 years
Recommended Phase 2 Dose (RP2D) of ES102 in combination with JS001
次要结局
- Area under the serum concentration time curve (AUC) of ES102 in combination with JS001(2-4 years)
- Maximum observed serum concentration of ES102 in combination with JS001(2-4 years)
- Time to Cmax (Tmax) of ES102 in combination with JS001(2-4 years)
- Trough observed serum concentration (Ctrough) of ES102 in combination with JS001(2-4 years)
- Immunogenicity of ES102 in combination with JS001(2-4 years)
- Anti-tumor activity of ES102 in combination with JS001(2-4 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid TumorsSolid TumorsNeoplasmsMalignant TumorNCT04730843Elpiscience Biopharma, Ltd.18
终止
1 期
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid TumorsSolid TumorsNeoplasmsMalignant TumorNCT04009460Elpiscience Biopharma, Ltd.22
招募中
1 期
Study of SGR-1505 in Mature B-Cell NeoplasmsMature B-Cell NeoplasmNon Hodgkin LymphomaWaldenstrom MacroglobulinemiaMALT LymphomaPediatric-Type Follicular LymphomaFollicular LymphomaDLBCLIRF4 Gene RearrangementEBV-Positive DLBCL, NosBurkitt LymphomaPlasmablastic LymphomaHigh-grade B-cell LymphomaDLBCL Germinal Center B-Cell TypePrimary Mediastinal Large B Cell LymphomaT-Cell/Histiocyte Rich LymphomaALK-Positive Large B-Cell LymphomaPrimary Cutaneous Diffuse Large B-Cell LymphomaSplenic Marginal Zone LymphomaNodal Marginal Zone LymphomaHHV8-Positive DLBCL, NosLymphoplasmacytic LymphomaDuodenal-Type Follicular LymphomaChronic Lymphocytic LeukemiaMantle Cell LymphomaPrimary Cutaneous Follicle Center LymphomaPrimary Effusion LymphomaNCT05544019Schrödinger, Inc.98
已完成
1 期
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesDiffuse Large B-cell LymphomaMultiple MyelomaAcute Myeloid LeukemiaNCT03106428MedImmune LLC67
已完成
1 期
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid TumorsSolid TumorCarcinomaCancerNCT02867007Kyowa Kirin, Inc.36